Like a lot of companies, we at AIQ have spent the last couple of years trying to navigate the hype and figure out real nuts-and-bolts applications for LLMs in our organization. As a medical device software start-up, we have a lot of reasons to be excited. Our team is small and nimble with a science and engineering focus. Just the right people to put AI tools to great use across everything we do.

AIQ Solutions President and CEO Eric Horler recently joined Scott Christiansen on The Root3Pointers Podcast for a conversation about AIQ’s work in late-stage and metastatic cancer care

In the episode, Eric discusses how TRAQinform IQ helps clinicians better understand treatment response across individual tumors, including when tumors in the same patient respond differently to treatment. He also shares perspective on AIQ’s approved CPT code, research partnerships, startup culture, and what’s ahead for the company.

In honor of Women’s History Month, AIQ Solutions is proud to recognize some of the incredible women helping advance what is possible in medicine and improve how care is delivered to patients with cancer. 

Across clinical, technical, and partnership roles, these individuals contribute to the development and adoption of TRAQinform IQ technology. Their work supports clinicians with clearer, more reliable insights to help guide treatment decisions. 

AIQ Solutions is proud to share that we have secured a sixth patent for our AI-enabled late-stage cancer analysis technology (U.S. Patent No. 12,562,258). 

CPT code is a major milestone to scale late-stage cancer analysis technology across the healthcare system 

AIQ Solutions today announced a significant advancement in the fight against late-stage cancer. After years of rigorous clinical, regulatory, and operational work by AIQ, the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code describing the unique output of AIQ’s TRAQinform IQ technology. This milestone will help make advanced treatment response intelligence more accessible to oncologists and the patients who need it most.